Publication
Modeling suggests that multiple immunizations or infections will reveal the benefits of updating SARS-CoV-2 vaccines
Downloadable Content
- Persistent URL
- Last modified
- 09/09/2025
- Type of Material
- Authors
- Language
- English
- Date
- 2022-05-23
- Publisher
- NIH
- Publication Version
- Copyright Statement
- The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
- License
- Final Published Version (URL)
- Title of Journal or Parent Work
- Volume
- 2022
- Abstract
- When should vaccines to evolving pathogens such as SARS-CoV-2 be updated? Our computational models address this focusing on updating SARS-CoV-2 vaccines to the currently circulating Omicron variant. Current studies typically compare the antibody titers to the new variant following a single dose of the original-vaccine versus the updated-vaccine in previously immunized individuals. These studies find that the updated-vaccine does not induce higher titers to the vaccine-variant compared with the original-vaccine, suggesting that updating may not be needed. Our models recapitulate this observation but suggest that vaccination with the updated-vaccine generates qualitatively different humoral immunity, a small fraction of which is specific for unique epitopes to the new variant. Our simulations suggest that these new variant-specific responses could dominate following subsequent vaccination or infection with either the currently circulating or future variants. We suggest a two-dose strategy for determining if the vaccine needs updating and for vaccinating high-risk individuals.
- Author Notes
- Keywords
Tools
- Download Item
- Contact Us
-
Citation Management Tools
Relations
- In Collection:
Items
| Thumbnail | Title | File Description | Date Uploaded | Visibility | Actions |
|---|---|---|---|---|---|
|
|
Publication File - vz4dv.pdf | Primary Content | 2025-05-21 | Public | Download |